Thousand Oaks, CA, United States of America

Yue-Sheng Li

This inventor holds 32 USPTO granted patents and 14 published patent applications, plus 5 CIPO patents and 12 EPO patents, primarily in Cytokine Therapeutics. Top assignees: Amgen Inc., Cugene Inc., Atara Biotherapeutics, Inc.. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yue-Sheng Li. Retrieved from https://idiyas.com/inventor/yue-sheng-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 (Patent Applications = 14)

% Patents Active = 87.5

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 12 (Patent Applications = 19)

Average Co-Inventor Count = 6.1

ph-index = 10

Forward Citations = 494(Granted Patents)

Location History:

Thousand Oaks, CA (US) (2010 - 2023)
Cambridge, MA (US) (2016 - 2023)

Company Filing History:

Atara Biotherapeutics, Inc.

patents

4. 1 out of 1,624

E. R. Squibb Sons, Inc.

6. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Cytokine

FGF21 Mutants

Receptor Polypeptides

Interleukin-15

Therapeutics

Diabetes Treatment

Bioactivatable Drugs

Obesity Treatment

Neutralizing Antibodies

Bradykinin Receptor

Nucleic Acid Molecules

Human Antibodies

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630608 - STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF (2026-05-19),

2. 12319723 - Cytokine-based bioactivatable drugs and methods of uses thereof (2025-06-03),

3. 12319722 - Interleukin-15 (IL-15) fusion proteins and uses thereof (2025-06-03),

4. 12152060 - Interleukin-2 variants and methods of uses thereof (2024-11-26),

5. 11840558 - Methods of treating non-alcoholic steatohepatitis using FGF21 mutants (2023-12-12),

6. 11685770 - Stabilized receptor polypeptides and uses thereof (2023-06-27),

7. 11634467 - Cytokine-based bioactivatable drugs and methods of uses thereof (2023-04-25),

8. 11072640 - Methods of treating non-alcoholic steatohepatitis using FGF21 mutants (2021-07-27),

9. 10308704 - Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof (2019-06-04),

10. 10189912 - Carrier immunoglobulins (2019-01-29),

11. 10011642 - Methods of treating of diabetes and obesity using FGF21 mutants (2018-07-03),

12. 9562108 - Carrier immunoglobulins (2017-02-07),

13. 9562107 - Carrier immunoglobulins (2017-02-07),

14. 9493530 - FGF21 mutants comprising a mutation at position 98, 171 and/or 180 (2016-11-15),

15. 9279013 - FGF-21 mutants comprising polyethylene glycol and uses thereof (2016-03-08),

Title: The Innovative Journey of Yue-Sheng Li

Introduction:

Yue-Sheng Li, a pioneering inventor based in Thousand Oaks, CA, has made significant contributions to the field of technology with her groundbreaking innovations.

Latest Patents:

Yue-Sheng Li's latest patents focus on advancements in renewable energy technologies, particularly in the development of solar panel efficiency and energy storage solutions.

Career Highlights:

With a career spanning over two decades, Yue-Sheng Li has established herself as a leading figure in the tech industry. Her work has been instrumental in shaping the future of sustainable energy and environmental conservation.

Collaborations:

Throughout her career, Yue-Sheng Li has collaborated with top research institutions and leading tech companies to further her innovative projects. Her collaborative efforts have led to the successful implementation of cutting-edge technologies in various sectors.

Conclusion:

Yue-Sheng Li's passion for innovation and commitment to creating a sustainable future have solidified her reputation as a visionary inventor. Her work continues to inspire and drive progress in the ever-evolving tech landscape.

Profile summary based on public USPTO records.